bighatbiosciences
Develops antibody therapies using artificial intelligence and synthetic biology.
Company facts
- Founded
- 2019
- Employees
- 98
- Headquarters
- United States
- CEO
- Mark DePristo
- Type
- Private
- Funding
- Series B · $124M · 2025
- Subsidiaries
- Frugi Biotechnology
About
BigHat Biosciences specializes in the development of next-generation antibody therapies utilizing machine learning and synthetic biology. Founded in 2019, our company is dedicated to creating safer and more effective treatments for patients affected by challenging diseases. Our mission is propelled by our Milliner™ platform, which integrates high-speed wet lab capabilities with advanced machine learning technologies to improve biologic drug development. At BigHat, we have cultivated a high-performance culture that prioritizes excellence while ensuring a family-friendly work environment. We engage in strategic partnerships to tackle complex therapeutic challenges and have raised over $100 million from esteemed investors, reflecting confidence in our innovative approach. Our team — composed of scientists, engineers, and problem solvers — continuously strives to revolutionize antibody design and engineering. By harnessing the power of AI, we aim to lead the charge in biotherapeutics and build a healthier future for patients globally.